Tigermed net profit plunges, shuffles investment strategy, plans stock buyback

Hangzhou Tigermed Consulting (SZSE:300347) announced a significant 79.99% year-over-year plunge in net profit, totaling 405.14 million CNY in 2024 in its annual audit report, signaling a notable shift in the company's financial strategy. The company simultaneously revealed plans for a stock buyback and alterations to its asset management approach. Amidst the profit drop, the firm highlighted a proposed cash dividend of 3 CNY per 10 shares, and plans to use the funds for supporting its growth in 2025, which has been approved and is awaiting shareholder vote.